What is the standard initial therapy for active tuberculosis and the general approach to latent tuberculosis?

What is the standard initial therapy for active tuberculosis and the general approach to latent tuberculosis?

• A. Active TB: RIPE for 2 months, then isoniazid + rifampin for 4 months; latent TB: isoniazid for 6-9 months or rifampin for 4 months
• B. Active TB: INH only for 9 months; latent TB: RIPE for 2 months
• C. Active TB: RIPE for 4 months; latent TB: rifampin for 3 months
• D. Active TB: RIPE for 2 months, then INH + rifampin for 4 months; latent TB: isoniazid for 6-9 months or rifampin for 4 months

Answer: (D)

Treating active tuberculosis relies on two phases: an initial intensive phase with multiple drugs to rapidly reduce the bacillary load and prevent resistance, followed by a continuation phase with a subset of those drugs to complete at least six months of therapy. The standard approach for drug-susceptible TB is RIPE—rifampin, isoniazid, pyrazinamide, and ethambutol—for two months, then a continuation phase of isoniazid plus rifampin for four additional months. This two-step plan ensures both rapid killing of active bacteria and continued suppression of any remaining organisms. For latent TB infection, the goal is to prevent progression to active disease with shorter, safer regimens. The common options are isoniazid for six to nine months or rifampin for four months, recognizing that either choice reduces the risk of future active TB. Other regimens aren’t appropriate for latent TB because they either involve unnecessary drugs or longer durations than needed. So the option described matches the accepted practice: active TB treated with RIPE for two months followed by isoniazid and rifampin for four months, and latent TB treated with isoniazid for six to nine months or rifampin for four months.

Treating active tuberculosis relies on two phases: an initial intensive phase with multiple drugs to rapidly reduce the bacillary load and prevent resistance, followed by a continuation phase with a subset of those drugs to complete at least six months of therapy. The standard approach for drug-susceptible TB is RIPE—rifampin, isoniazid, pyrazinamide, and ethambutol—for two months, then a continuation phase of isoniazid plus rifampin for four additional months. This two-step plan ensures both rapid killing of active bacteria and continued suppression of any remaining organisms.

For latent TB infection, the goal is to prevent progression to active disease with shorter, safer regimens. The common options are isoniazid for six to nine months or rifampin for four months, recognizing that either choice reduces the risk of future active TB. Other regimens aren’t appropriate for latent TB because they either involve unnecessary drugs or longer durations than needed.

So the option described matches the accepted practice: active TB treated with RIPE for two months followed by isoniazid and rifampin for four months, and latent TB treated with isoniazid for six to nine months or rifampin for four months.